跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SIMLANDI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SIMLANDI
Authorized
STANDARD
SIMLANDI
Jamp Pharma Corporation
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
58c915a8512f628e
Company
Jamp Pharma Corporation
Type
Standard
Approval Details
Approval Id
58c915a8512f628e
Drug Approval Canada Name
SIMLANDI
Product Name
SIMLANDI
Status
Marketed
Status Date
2022-04-13
Original Market Date
2022-04-13
Din
02523957
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
90:24.16.92
Atc Original
L04AB04 ADALIMUMAB
Atc Name
l 04 ab 04
Aig Number
0150364002
Company Name
Jamp Pharma Corporation
Company Address
1310 Rue Nobel, Boucherville, Quebec, Canada, J4B 5H3
Company Detail Path
/organization/jamp-pharma-corporation
Company Information
Pharmaceutical Company Name
Jamp Pharma Corporation
Country Name
Canada
Province Name
British Columbia
City Name
chilliwack,british columbia,country_ca
Address
8065 Aitken Rd
Active Ingredients
ADALIMUMAB
40 MG / 0.4 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
58c915a8512f628e
Type
Standard
Back to Health Canada Approvals